BTK and COVID-19: Further, a Bruton tyrosine kinase (BTK) inhibitor was also found to reduce BTK-dependent activation of NF-κB and NLRP3 inflammasome, which suppressed pro-inflammatory factors production and COVID-19 cytokine storm, thereby improving the prognosis of COVID-19 patients (Roschewski et al., 2020).